Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952253 | 0.89 | SLC6A4 (0.64) | HTR2ASLC6A4KCNH2AAK1 | |
| SCHEMBL2547551 | 0.80 | IDO1 (0.52) | AAK1IDO1NQO2KDM4EMEN1 | |
| SCHEMBL2881204 | 0.79 | SLC6A4 (0.55) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL2552330 | 0.75 | AAK1 (0.50) | AAK1IDO1NQO2KDM4EMEN1 | |
| SCHEMBL2520675 | 0.75 | AAK1 (0.46) | AAK1IDO1HPGDSMN1; SMN2 | |
| SCHEMBL31142926 | 0.75 | AAK1 (0.46) | AAK1IDO1HPGDSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL3942675 | 0.74 | SLC6A4 (0.71) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL4930587 | 0.74 | AAK1 (0.48) | AAK1IDO1NQO2ALDH1A1HPGD | |
| SCHEMBL29888968 | 0.74 | NQO2 (0.50) | AAK1IDO1NQO2KDM4EMEN1 | |
| SCHEMBL25834169 | 0.73 | TSHR (0.54) | IDO1NQO2KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HTR2A 15/4885SLC6A4 8/4885KCNH2 1234/4885 |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HTR2A 15/4885SLC6A4 8/4885KCNH2 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.